Tempus AI, Inc. (NASDAQ:TEM) COO Sells $792,200.00 in Stock

Tempus AI, Inc. (NASDAQ:TEM) COO Ryan Fukushima sold 20,000 shares of the company’s stock in a transaction on Tuesday, January 7th. The stock was sold at an average price of $39.61, for a total transaction of $792,200.00. Following the completion of the transaction, the chief operating officer now directly owns 982,442 shares of the company’s stock, valued at $38,914,527.62. This represents a 2.00 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this link.

Ryan Fukushima also recently made the following trade(s):

• On Monday, December 16th, Ryan Fukushima sold 3,500 shares of Tempus AI stock. The stock was sold at an average price of $40.23, for a total transaction of $140,805.00.
• On Wednesday, December 11th, Ryan Fukushima sold 120,000 shares of Tempus AI stock. The stock was sold at an average price of $42.51, for a total transaction of $5,101,200.00.

Tempus AI Price Performance

Shares of NASDAQ TEM opened at $37.52 on Friday. The firm’s 50-day moving average price is $48.45 and its 200-day moving average price is $46.89. The company has a debt-to-equity ratio of 8.17, a quick ratio of 2.55 and a current ratio of 2.69. Tempus AI, Inc. has a 12-month low of $22.89 and a 12-month high of $79.49.

Analyst Ratings Changes

Several brokerages recently weighed in on TEM. Stifel Nicolaus downgraded shares of Tempus AI from a “buy” rating to a “hold” rating and upped their target price for the stock from $45.00 to $65.00 in a report on Monday, November 11th. Bank of America increased their price objective on shares of Tempus AI from $52.00 to $54.00 and gave the company a “neutral” rating in a report on Friday, December 13th. Piper Sandler reissued a “neutral” rating and set a $70.00 price objective (up previously from $40.00) on shares of Tempus AI in a report on Tuesday, November 12th. Loop Capital increased their price objective on shares of Tempus AI from $48.00 to $57.00 and gave the company a “buy” rating in a report on Tuesday, October 15th. Finally, Wolfe Research started coverage on shares of Tempus AI in a report on Friday, December 13th. They set an “outperform” rating and a $60.00 price objective for the company. Three investment analysts have rated the stock with a hold rating and nine have issued a buy rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $56.00.

Institutional Trading of Tempus AI

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Silverleafe Capital Partners LLC purchased a new stake in Tempus AI in the 4th quarter worth about $533,000. Franklin Resources Inc. raised its position in Tempus AI by 1.0% in the 3rd quarter. Franklin Resources Inc. now owns 811,311 shares of the company’s stock worth $45,920,000 after purchasing an additional 8,387 shares during the period. Tidal Investments LLC purchased a new stake in Tempus AI in the 3rd quarter worth about $7,633,000. Teachers Retirement System of The State of Kentucky raised its position in Tempus AI by 6.3% in the 3rd quarter. Teachers Retirement System of The State of Kentucky now owns 126,500 shares of the company’s stock worth $7,160,000 after purchasing an additional 7,500 shares during the period. Finally, Geode Capital Management LLC raised its position in Tempus AI by 0.4% in the 3rd quarter. Geode Capital Management LLC now owns 133,171 shares of the company’s stock worth $7,537,000 after purchasing an additional 539 shares during the period. 24.22% of the stock is owned by hedge funds and other institutional investors.

Tempus AI Company Profile

Tempus AI Inc is a technology company advancing precision medicine through the practical application of artificial intelligence principally in healthcare. The company provides AI-enabled precision medicine solutions to physicians to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics.